Cetuximab plus irinotecan in pretreated metastatic colorectal cancer patients:The ELSIE study

查看全文 作　　者：Robert [1]Lim;Yan [2]Sun;Seock-Ah [3]Im;Ruey-Kuen [4]Hsieh;Tsz Kok [5]Yau;Anthony [6]Bonaventura;Arkom [7]Cheirsilpa;Regina [8]Esser;Matthias [9]Mueser;Suresh [10]Advani

机构地区：[1]Department of Hematology-Oncology, National University Hospital, 119074 Singapore, Singapore;[2]Department of Medical Oncology, Cancer Hospital and Institute, Chinese Academy of Medical Science, Beijing 100021, China;[3]Division of Hematology-Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul 110-744, South Korea;[4]Department of Oncology-Hematology, Mackay Memorial Hospital, Taipei 104, Taiwan, China;[5]Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Hong Kong, China;[6]Department of Medical Oncology, Calvary Mater Newcastle Hospital, Waratah, New South Wales, 2298. Australia;[7]National Cancer Institute, Bangkok, 10400, Thailand;[8]Global Clinical Development Unit Oncology, Merck KGaA, Darmstadt, 64293, Germany;[9]Medical Affairs Oncology Asia Pacific, Merck Serono, 609927 Singapore, Singapore;[10]Jaslok Hospital and Research Centre, Mumbai 400026, India

出　　处：《World Journal of Gastroenterology》索引2011年第17卷第14期,共10页

基　　金：Supported by Merck KGaA, Darmstadt, Germany 摘　　要：AIM:To evaluate the efficacy and safety of cetuxim-ab plus irinotecan in irinotecan-refractory metastatic colorectal cancer (mCRC) patients from South-East Asia and Australia. METHODS:In this open-label,phase Ⅱ study,the main eligibility criteria were epidermal growth factor receptor-positive mCRC with progressive disease within 3 mo of an irinotecan-based regimen as the most recent chemotherapy. Patients received cetuximab 400 mg/m2 initially,then 250 mg/m2 every week,with the same regimen of irinotecan on which the patients had progressed (4 pre-defined regim-ens allowed). The prim-ary objective was evaluation of progression-free survival (PFS) at 12 wk. Secondary objectives included a further investigation of PFS,and an assessment of the overall response rate (ORR),duration of response,time to treatment failure (TTF),overall survival and the safety profile. RESULTS:One hundred and twenty nine patients were enrolled from-25 centers in the Asia-Pacific region and of these 123 received cetuximab plus irinotecan. The most common recent irinotecan regimen used was 180 mg/m2 every 2 wk which had been used in 93 patients (75.6%). The PFS rate at 12 wk was 50% (95% confidence interval (CI,41-59) and m-edian PFS tim-e was 12.1 wk (95% CI:9.7-17.7). The ORR was 13.8% (95% CI:8.3-21.2) and disease control rate was 49.6% (95% CI:40.5-58.8). Median duration of response was 31.1 wk (95% CI:18.0-42.6) and median overall survival was 9.5 mo (95% CI,7.5-11.7). The median TTF was 11.7 wk (95% CI:9.1-17.4). Treatment was generally well tolerated. The most common grade 3/4 adverse events were diarrhea (13.8%),neutropenia (8.9%),rash (5.7%) and vomiting (5.7%).CONCLUSION:In patients from Asia and Australia,this study confirm-s the activity and safety of cetuxim-ab plus irinotecan observed in previous studies in Europe and South America. 关键词：结直肠癌转移性患者单抗预处理表皮生长因子受体响应时间澳大利亚

相关文献

参考文献（28）
引证文献（1）
耦合文献（0）

参考文献(28)

引证文献(1)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

Cetuximab plus irinotecan in pretreated metastatic colorectal cancer patients:The ELSIE study

参考文献(28)

引证文献(1)

用户提示